A PHASE 2, RANDOMIZED, DOUBLE-BLIND, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA VACCINES AGAINST INFLUENZA IN ADULTS 18 YEARS OF AGE AND OLDER
Status: Recruiting
Location: See all (15) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus). This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison. Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• • Healthy and medically stable participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study.
Locations
United States
Alabama
AMR Clinical
NOT_YET_RECRUITING
Mobile
California
Diablo Clinical Research, LLC d/b/a Flourish Research
RECRUITING
Walnut Creek
Connecticut
Clinical Research Consulting, LLC
RECRUITING
Milford
Washington, D.c.
George Washington Medical Faculty Associates
RECRUITING
Washington D.c.
Florida
Indago Research & Health Center, Inc
RECRUITING
Hialeah
Palm Springs Community Health Center
RECRUITING
Miami Lakes
Georgia
Clinical Research Atlanta
RECRUITING
Stockbridge
Hawaii
East-West Medical Research Institute
RECRUITING
Honolulu
Missouri
AMR Clinical
NOT_YET_RECRUITING
Kansas City
New York
Rochester Clinical Research, LLC
RECRUITING
Rochester
Pennsylvania
DM Clinical Research - Philadelphia
RECRUITING
Philadelphia
Texas
SMS Clinical Research LLC
RECRUITING
Mesquite
DM Clinical Research
RECRUITING
Tomball
Utah
J. Lewis Research, Inc. / Foothill Family Clinic
RECRUITING
Salt Lake City
Virginia
Charlottesville Medical Research Center, LLC
RECRUITING
Charlottesville
Contact Information
Primary
Pfizer CT.gov Call Center
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Time Frame
Start Date:2026-02-23
Estimated Completion Date:2027-06-22
Participants
Target number of participants:770
Treatments
Experimental: A
mRNA influenza vaccine candidate #1 as a single intramuscular (IM) injection on Day 1.
Experimental: B
mRNA influenza vaccine candidate #2 as a single IM injection on Day 1.
Experimental: C
mRNA influenza vaccine candidate #3 as a single IM injection on Day 1.
Experimental: D
mRNA influenza vaccine candidate #4 as a single IM injection on Day 1.
Experimental: E
mRNA influenza vaccine candidate #5 as a single IM injection on Day 1.
Experimental: F
mRNA influenza vaccine candidate #6 as a single IM injection on Day 1.
Active_comparator: G
Licensed influenza vaccine (TIV1 or TIV2) as a single IM injection.